clinical trial · NCT03764618
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Warm Antibody Autoimmune Hemolytic AnemiaFostamatinib disodiumPlacebo
brief summary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
started
Apr 24, 2019
primary completion
Apr 11, 2022
completion
Apr 11, 2022
last updated
May 25, 2023
official title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol